IN2Pharma SA
15.1 FTEIN2Pharma reported total assets of €1.48m at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Jun 2026), with 15.1 full-time equivalents.
The score of IN2Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets +24 % Headcount (avg FTE) +70 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
IN2Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Jun 2026
- Year ended 31 Dec 2024filed on 10 Jul 2025
- Year ended 31 Dec 2023filed on 15 May 2024
- Year ended 31 Dec 2022filed on 18 Jul 2023
- Year ended 31 Dec 2021filed on 15 Mar 2022
IN2Pharma's financial analysis
- Solvency4.7%sector median: 58.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of IN2Pharma
IN2Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0895.730.662
- VAT number
- BE0895730662
- Peppol
- Registered · 0208:0895730662 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 29 Jan 2008
- Registered office
- 1910 Kampenhout
- Size
- Small · 15.1 FTE
- Latest accounts
- 2025 · filed on 22 Jun 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
IN2Pharma (SA) has been based in Kampenhout since 2008, active in: business and other management consultancy activities. For 2025, it reports a net profit of 909,969 € and equity of 69,300 €; its revenue is not published. With 15.1 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 4.7%, below the median of its sector (58.4%).
Companies similar to IN2Pharma
Companies in the same business, of comparable size and area, outside its group.
- Oxylium Consulting Business and other management consultancy activities Alken · balance sheet 58,729 €
- Fiscal Solutions Business and other management consultancy activities Hamme (Vl.) · balance sheet 77,466 €
- Jacobs Andre Advies EN Consulting Business and other management consultancy activities Malmedy · balance sheet 8,426 €
- Aviscare Business and other management consultancy activities Liège · balance sheet 866,622 €
- Data Leverage Business and other management consultancy activities Ottignies-Louvain-la-Neuve · balance sheet 37,248 €
- Osman Emir Management Business and other management consultancy activities Sint-Niklaas · balance sheet 87,707 €
- Namik Talia Management Business and other management consultancy activities Sint-Niklaas · balance sheet 182,522 €
- DORO Business and other management consultancy activities Kuurne · balance sheet €1.57m
Frequently asked questions about IN2Pharma
What is the revenue of IN2Pharma?
IN2Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of IN2Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0895730662 for IN2Pharma, if the company is VAT-registered. Its company number (CBE) is 0895.730.662.
Where is the registered office of IN2Pharma?
According to the CBE register, the registered office of IN2Pharma is in 1910 Kampenhout.
What is the equity of IN2Pharma?
At the close of the 2025 financial year, the equity of IN2Pharma amounts to 69,300 €, a solvency of 4.7% of total assets.
How many people work at IN2Pharma?
15.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages IN2Pharma?
The register lists 5 active mandates at IN2Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of IN2Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →